Monulparivir Could Stop the Virus in 24 Hours

Google+ Pinterest LinkedIn Tumblr +

Scientists at Institute for Biomedical Sciences, Georgia State University, Atlanta may have made a long-awaited breakthrough. Because they have tested new anti-viral drug MK-4482 / EIDD-2801 on otters, and found this blocks COVID-19 transmission. Moreover, Enterpreneur.Com suggests this drug, Monulparivir could stop the virus spreading within 24 hours if administered to human patients.

Imagine if Monulparivir Could Stop the Virus in Its Tracks

A team at Emory University in Atlanta developed the antiviral drug to treat flu. But it also holds promise not of preventing COVID as a vaccine, but of preventing spreading as a medication. Therefore this could be incredibly important in the light of naysayers refusing vaccines. And in addition by implication continuing to promote the COVID-19 pandemic.

A report in Nature Microbiology Journal describes how infected ferrets responded to the drug, first by reducing their viral particles. And then by being unable to infect other healthy ferrets, when together in the same enclosure. Drug Innovation Ventures at Emory actually developed Monulparivir to treat the flu, and prevent that virus from making copies of itself. And while this is currently in advanced phase II / III clinical trials, this new opportunity has emerged.

What a Wonderful Bonus If This Works on Humans

If Monulparivir could stop the COVID virus spreading as effectively in humans as in ferrets, it could be a game changer. That’s because patients would be able to take it orally by swallowing, and obtain these three benefits according to Entrepreneur.Com:

1… Hinder or prevent their disease becoming serious

2… Shorten the length and cost of their infectious phase

3… Quickly dampen down local outbreaks and block them

This work appears to be the first emergence of a drug that could effectively block the transmission of SARS-CoV-2. As such, it’s a wonderful opportunity to tackle a terrible disease, and on a scale we might not have thought possible before.

Related

Using Airflow to Reduce Infections in Autos

Difficult Time in US Public Health History

Preview Image: Testing Monulparivir on Ferrets

Nature Microbiology Journal Report

Share.

About Author

Electricity has always intrigued me. I have been writing about batteries and energy storage for more than ten years, and have published over 4,000 articles on this website. During that time, I have researched developments across lead-acid, lithium-ion, sodium-ion, flow batteries, and emerging energy-storage technologies. My goal is to explain complex battery concepts in clear, practical language that anyone can understand. My writing career began unexpectedly after leaving the corporate world. What started as a search for a new direction gradually became a fascination with batteries, renewable energy, and the science that powers modern life. Writing may not have made me wealthy, but it has given me the opportunity to explore an industry that continues to evolve in remarkable ways.

Leave A Reply